Literature DB >> 27083774

Is suicide assessment harmful to participants? Findings from a randomized controlled trial.

Keith M Harris1, Melissa Ting-Ting Goh2.   

Abstract

There is considerable debate on whether suicide assessment carries an iatrogenic risk for participants/patients. A double-blind randomized controlled trial (registration: R000022314) tested the emotional impact of suicide assessment on participants (n = 259) randomly assigned to experimental (n = 122) or control conditions (n = 137). The experimental condition included the Suicidal Affect-Behavior-Cognition Scale and intensive death-related questions, the control condition a quality of life scale. Both included measures of depression, social support and loneliness. Affective states were assessed immediately before and after testing, and research biases minimized. Post-test debriefing interviews collected qualitative reactions. Experimental participants ranged from nonsuicidal to highly suicidal. Between-groups ANCOVAs and repeated measures ANOVAs showed no differences by study condition, and no pre-post-test affect changes for either condition or suicidal participants (P > 0.10), supporting the null hypothesis of no iatrogenic effects. However, depressive participants in both conditions showed significant decreases in positive affect (P < 0.05). Smallest real difference (SRD) scores approximated clinically meaningful differences and showed 20% of participants had a significant positive survey reaction, 24% a negative reaction, with the rest neutral. Linear regressions revealed depressive symptoms and perceived family support, but not suicidality or other factors, predicted negative affect changes, which was supported by qualitative findings. Social desirability bias was also found in qualitative survey responses. No evidence of iatrogenic effects of suicide assessment were found. Recommendations are made to counter possible negative assessment effects on depressive participants/patients, and nurses and other caregivers are encouraged to talk to patients about suicidal symptoms.
© 2016 Australian College of Mental Health Nurses Inc.

Entities:  

Keywords:  assessment; depression; research bias; suicide prevention; survey

Mesh:

Year:  2016        PMID: 27083774     DOI: 10.1111/inm.12223

Source DB:  PubMed          Journal:  Int J Ment Health Nurs        ISSN: 1445-8330            Impact factor:   3.503


  6 in total

1.  The risk-benefit ratio of studying psychiatric symptoms via daily diary methods.

Authors:  Caitlin Wolford-Clevenger; Mickeah J Hugley; James McNulty; Lawrence Christian Elledge; Karen Cropsey; Gregory L Stuart
Journal:  Account Res       Date:  2019-11-21       Impact factor: 2.622

2.  Psychiatric Distress and Suicidal Tendencies in Adult Cancer Survivors: Verifying the Validity of the Brief Symptom Inventory-18 for Identifying Suicidal Ideation in the Hospitalized Population of Mainland China.

Authors:  Fen Teng; Deying Hu; Yi Zhou; Yilan Liu; Yanhong Han; Ke Xu; Ting Yu; Rong Tan; Xiaoping Ding
Journal:  J Clin Psychol Med Settings       Date:  2022-01-25

3.  Robust suicide risk assessment on social media via deep adversarial learning.

Authors:  Ramit Sawhney; Harshit Joshi; Saumya Gandhi; Di Jin; Rajiv Ratn Shah
Journal:  J Am Med Inform Assoc       Date:  2021-07-14       Impact factor: 4.497

4.  Assessing Suicide Risk and Emotional Distress in Chinese Social Media: A Text Mining and Machine Learning Study.

Authors:  Qijin Cheng; Tim Mh Li; Chi-Leung Kwok; Tingshao Zhu; Paul Sf Yip
Journal:  J Med Internet Res       Date:  2017-07-10       Impact factor: 5.428

5.  Difference and Analysis of Evaluating Psychological Monitors' Interview and Classmates' Being Interviewed About Suicide.

Authors:  Qisheng Zhan; Tianyu Xia
Journal:  Front Psychol       Date:  2022-06-20

6.  Research on the pathophysiology, treatment, and prevention of suicide: practical and ethical issues.

Authors:  Allison C Nugent; Elizabeth D Ballard; Lawrence T Park; Carlos A Zarate
Journal:  BMC Psychiatry       Date:  2019-11-01       Impact factor: 3.630

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.